Cytokine-based Biologic Agent IRX-2

Phase 1Biologic

Cytokine-based Biologic Agent IRX-2 is one of 18 biologic programs targeting Gastroesophageal Junction Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction CancerCompleted

Recurrent Hepatocellular CarcinomaActive, not recruiting

Gastroesophageal Junction CancerPreclinical

Completed

Recurrent Hepatocellular CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Gastroesophageal Junction Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

9 2

Eloxatin

Teva

Phase 3

9 3

Cyramza

Eli Lilly

Phase 3

6 4

Keytruda

Merck & Co.

Phase 3

2 5

Imfinzi

AstraZeneca

Phase 3

1 6

Adrucil

EElorac, Inc.

Phase 3

8 7

Taxotere

AAvyxa

Phase 3

8 8

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

2 9

FLOT Alone

AstraZeneca

Phase 3

1 10

Trifluridine and Tipiracil Hydrochloride

RRoswell Park Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Recurrent Hepatocellular Carcinoma

NCT03655002

Clinical

Trials by Indication[1]

Clinical Stage IV Gastric Cancer AJCC v81 trial

A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed·CCity of Hope Medical Center·Preclinical·NCT03918499·9 enrolled

Recurrent Hepatocellular Carcinoma1 trial

A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT03655002·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cytokine-based Biologic Agent IRX-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytokine-based Biologic Agent IRX-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytokine-based Biologic Agent IRX-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

Cytokine-based Biologic Agent IRX-2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Clinical Stage IV Gastric Cancer AJCC v81 trial

Recurrent Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News